Background: Primary pancreatic signet ring cell carcinoma (PSRCC), an extremely rare histologic variant of pancreatic cancer, has a poor prognosis. This study aimed to investigate the prognostic value of chemotherapy in PSRCC. Methods: Patients with PSRCC between 2000 and 2019 were identified using the Surveillance Epidemiology and End Results (SEER) database. The main outcomes in this study were cancer-specific survival (CSS) and overall survival (OS). The baseline characteristics of patients were compared using Pearson’s Chi-square test. Kaplan-Meier analysis was used to generate the survival curves. Least absolute shrinkage and selection operator (LASSO), univariate and multivariate Cox regression models, and Random Survival Forest model were used to analyze the prognostic variables for OS and CSS. The variance inflation factors (VIFs) were used to analyze whether there was an overfitting problem. Results: A total of 588 patients were identified. Chemotherapy was an independent prognostic factor for OS and CSS, and significantly associated with OS (HR = 0.33, 95% CI = 0.27–0.40, P <0.001) and CSS (HR = 0.32, 95% CI = 0.26–0.39, P <0.001). Conclusions: Chemotherapy showed beneficial effects on OS and CSS in patients with PSRCC and should be recommended in clinical practice.
Background We aimed to study the prognostic risk factors affecting patients with anaplastic thyroid carcinoma (ATC), develop a clinical prognostic model, and assess patient survival outcomes. Methods Patients with anaplastic thyroid carcinoma from 2000 to 2019 were selected from the Surveillance, Epidemiology, and End Results (SEER) Program to extract the clinical variables used for analysis. The dataset was divided into training (70%) and validation (30%) sets based on a 7:3 ratio. Univariate and LASSO regression analyses were performed on clinical variables from the training set to identify independent prognostic factors. Independent prognostic factors were determined by Univariate and lasso regression according to the clinical variables of the training set, and a nomogram model was established to construct a prognostic model based on the contribution degree of the predictors. The prognostic model was evaluated and internally verified by C-index, ROC curve and calibration curve. Results A total of 713 ATC patients were included in the SEER database. LASSO regression results indicated that age, marital status, race, tumor size, whether the primary lesion was limited to the thyroid gland, surgery, radiotherapy and chemotherapy, were associated with overall survival(OS) prognosis of ATC, and were used to construct nomograms. In the training cohort, the OS nomogram’s C-index was 0.708 (95% CI 0.672–0.745); in the internal validation cohort, the C-index was 0.677 (95% CI 0.620–0.735). ROC curves demonstrated that the OS nomogram exhibits excellent predictive accuracy and discriminative ability. Calibration curves indicated strong consistency between the OS nomogram’s predicted survival rates and actual survival rates. Conclusions We established a survival prediction model for ATC, which can assist clinicians in assessing patient prognosis and making personalized treatment decisions.
15 July 2026 in Diabetes/Metabolism Research and Reviews
Objective Primary pancreatic signet ring cell carcinoma (PSRCC) is an extremely rare histologic variant of pancreatic cancer with a worse prognosis. The present study aimed to investigate the prognostic value of chemotherapy for patients with PSRCC.Methods Patients with PSRCC between 2000 and 2019 were identified Using the Surveillance Epidemiology and End Results (SEER) database. The main outcomes in our study were cancer-specific survival (CSS) and overall survival (OS). Patient baseline characteristics were compared using Pearson’s chi-square test. Kaplan-Meier analysis was used to generate the survival curves. Least absolute shrinkage and selection operator (lasso) as well as univariate and multivariate Cox regression models were used to analyze the prognostic variables on OS and CSS.Results A total of 588 patients with PSRCC were identified. Chemotherapy was an independent prognostic factor for OS and CSS, and significantly associated with OS (HR = 0.33, 95% CI = 0.27–0.40, P < 0.001) and CSS (HR = 0.32, 95% CI = 0.26–0.39, P < 0.001).Conclusions Patients with PSRCC can benefit from chemotherapy, so it should be recommended to patients with PSRCC, especially those not suitable for surgery.
Background: ZNF25 , a KRAB domain-containing zinc finger transcription factor, has been identified as a potential biomarker in ovarian cancer. However, its pan-cancer significance and the underlying molecular mechanisms in other malignancies remain largely unclear. Methods: We performed a systematic pan-cancer analysis of ZNF25 using TCGA and GTEx databases, integrated with platforms including cBioPortal, TISIDB, TIMER, and Sangerbox. Associations between ZNF25 expression and clinical outcomes, genomic alterations, immune cell infiltration, and DNA methylation were systematically evaluated. Based on these findings, functional validation was performed in glioma cell lines (U87-MG and A172) via siRNA-mediated knockdown of ZNF25 , followed by cell viability assays, wound healing assays, and Western blot assays. Additionally, RNA-seq was conducted in ZNF25 - knockdown U87-MG cells to identify differential expression genes and enriched pathways. Results: ZNF25 exhibited significant associations with diagnostic potential, poor prognosis, and immune infiltration across multiple cancer types, with the most pronounced effects observed in glioma. Functional assays demonstrated that ZNF25 knockdown suppressed the proliferation and migration of glioma cells. Transcriptomic and biochemical analysis indicated that ZNF25 promotes glioma progression, at least in part, through the positive modulation of the PI3K-AKT pathway. Conclusions: Collectively, our findings identify ZNF25 as a potential diagnostic and prognostic biomarker across various cancers and suggest its critical role in glioma progression. This study provides new insights into the functional role of ZNF25 and highlights its potential as a therapeutic target, particularly in glioma.